How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The biopharmaceutical company had revenue of $15.17 million for the quarter, compared to the consensus estimate of $14.29 million. AVEO Pharmaceuticals had a negative trailing twelve-month return on equity of 81.66% and a negative net margin of 30.79%. During the same quarter in the prior year, the company earned ($0.33) EPS.

When did AVEO Pharmaceuticals' stock split?

AVEO Pharmaceuticals's stock reverse split before market open on Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO?

4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com . Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend.

What other stocks do shareholders of AVEO Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL) , Micron Technology (MU) , Advanced Micro Devices (AMD) , Inovio Pharmaceuticals (INO) , OPKO Health (OPK) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) , Corbus Pharmaceuticals (CRBP) , Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA) .

Who are AVEO Pharmaceuticals' major shareholders?

AVEO Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Michael Ferraresso and Michael P Bailey . View institutional ownership trends .

AVEO Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AVEO)

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $14.99
▼
$15.00
50-Day Range: $14.90
▼
$15.00
52-Week Range: $3.06
▼
$15.00

Volume: 247,800 shs
Average Volume: 601,442 shs
Market Capitalization: $521.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About AVEO Pharmaceuticals Stock (NASDAQ:AVEO)

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

November 30, 2023 | finance.yahoo.com

AVEO Oncology, an LG Chem company, Earns Spot on Boston Globe's 2023 Top Places to Work List for Second Consecutive Year

November 3, 2023 | finance.yahoo.com

Actinium Appoints Lynn Bodarky as Chief Business Officer

December 9, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

October 30, 2023 | afr.com

Brookfield finalises $1.45b debt refi for Aveo; lenders pile in

July 13, 2023 | afr.com

Brookfield locks in $1.45b debt refi for Aveo; five banks underwrite

May 10, 2023 | finance.yahoo.com

Actinium Pharma to Present at Guggenheim Healthcare Talks Radiopharmaceuticals Day

May 5, 2023 | marketwatch.com

2023 Kidney Cancer Market Size Growth Analysis by Absolute Reports | with [101 Pages] and Forecast till 2031

May 3, 2023 | marketwatch.com

C-MET & HGF Inhibitors Market Growth Opportunities and Emerging Trends till 2031

December 9, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

May 3, 2023 | marketwatch.com

FGF-2 Inhibitors Market 2023 SWOT Analysis and Demand Status Forecast by 2030

April 27, 2023 | marketwatch.com

C-MET / HGF Inhibitors Market Size [2023] Global Overview includes Market Trends and Forecast to 2027 | with [148 Pages]

April 27, 2023 | marketwatch.com

Hepatocyte Growth Factor Market Research Analysis 2023-2031

April 25, 2023 | marketwatch.com

Neuroendocrine Tumors Treatment Market 2023 to 2030 Market Analysis, Share, Size, Trends, Scope, Growth Drivers, By Top Companies And Forecast

April 23, 2023 | marketwatch.com

2023-2030 Kidney Cancer Treatment Drugs Market Share, Detailed Examination of Industry Trends and Opportunities

April 20, 2023 | marketwatch.com

Industry Research Report on C-MET / HGF Inhibitors Market Share and Industrial Overview till 2030

April 16, 2023 | marketwatch.com

C-MET / HGF Inhibitors Market Forecast to 2030

April 14, 2023 | msn.com

2024 Chevy Aveo: The Sonic Is Still Alive and Thriving, Just Not in the U.S.

April 12, 2023 | marketwatch.com

C-MET & HGF Inhibitors Market Growth by 2030

April 7, 2023 | marketwatch.com

2023 Cancer Drug Therapy Market: Projection up to 2027

April 5, 2023 | marketwatch.com

Kidney Cancer Drugs Market 2023 Size and Forecast to 2031

April 3, 2023 | thestreet.com

AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement

March 21, 2023 | marketwatch.com

Cancer Drug Therapy Market Size and Forecast till 2028

March 17, 2023 | marketwatch.com

Kidney Cancer Market 2023 Exploring New Challenges and Opportunities, Forecast to 2028

March 14, 2023 | marketwatch.com

Relapsed Acute Myeloid Leukemia Drug Market Size2023 Research Report by Segment Analysis and Forecast till 2027

March 14, 2023 | marketwatch.com

Hepatocyte Growth Factor Market Reliable Business Data Analysis and Forecast by 2028

March 9, 2023 | marketwatch.com

Future Outlook: Forecasting Kidney Cancer Targeted Therapy Market Trends in North America, Asia, Europe, and South America

March 8, 2023 | marketwatch.com

2023-2029 Kidney Cancer Treatment Drugs Market Size and Latest Trends Analysis | Research Report by Absolute Reports

See More Headlines

Receive AVEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2021
Today: 12/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:AVEO
CUSIP: 05358810
CIK: 1325879
Web: www.aveooncology.com
Phone: (617) 400-0101
Fax: 617-995-4995
Employees: 114
Year Founded: 2001

Profitability

EPS (Most Recent Fiscal Year): ($0.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-53,340,000.00
Net Margins: -30.79%
Pretax Margin: -30.79%
Return on Equity: -81.66%
Return on Assets: -28.83%

Debt

Debt-to-Equity Ratio: 0.94
Current Ratio: 2.37
Quick Ratio: 2.35

Sales & Book Value

Annual Sales: $42.29 million
Price / Sales: 12.33
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.33 per share
Price / Book: 11.28

Miscellaneous

Outstanding Shares: 34,763,000
Free Float: 33,619,000
Market Cap: $521.45 million
Optionable: Optionable
Beta: 1.00

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Michael P. Bailey
President, Chief Executive Officer & Director
Jebediah Ledell
Chief Operating Officer
Erick J. Lucera
Chief Financial Officer
Matthew Coulter
Vice President-Information Technology
Stefanie Solomon
Head-Compliance

Key Competitors

View All Competitors

AVEO Stock Analysis - Frequently Asked Questions

How were AVEO Pharmaceuticals' earnings last quarter?: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The biopharmaceutical company had revenue of $15.17 million for the quarter, compared to the consensus estimate of $14.29 million. AVEO Pharmaceuticals had a negative trailing twelve-month return on equity of 81.66% and a negative net margin of 30.79%. During the same quarter in the prior year, the company earned ($0.33) EPS.
When did AVEO Pharmaceuticals' stock split?: AVEO Pharmaceuticals's stock reverse split before market open on Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO?: 4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend.

What other stocks do shareholders of AVEO Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA).
Who are AVEO Pharmaceuticals' major shareholders?: AVEO Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Michael Ferraresso and Michael P Bailey.
View institutional ownership trends.

This page (NASDAQ:AVEO) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AVEO Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AVEO)

About AVEO Pharmaceuticals Stock (NASDAQ:AVEO)

AVEO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

AVEO Stock Analysis - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info